Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: S01AX24Orphan Medicine

Akantior(Polihexanide)

Acanthamoeba Keratitis

Marketing Authorisation Holder: SIFI SPA

EMA Authorisation: 22/08/2024

INN: polihexanide

Indication

Akantior is indicated for the treatment of Acanthamoeba keratitis in adults and children from 12 years of age.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Akantior — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.